Lin Y, Stephenson MC, Xin L, Napolitano A, Morris PG
Not sure if this suits you
This segment is expected to attract a growing share of prescriptions and patient interest as more oral formulations enter the market with proven efficacy
Dimitris Papamargaritis has acted as a speaker for Novo Nordisk, Eli Lilly and Boehringer Ingelheim and Johnson and Johnson and has received grants from Novo Nordisk, Novo Nordisk UK Research Foundation, Academy of Medical Sciences/Diabetes UK, Health Education East Midlands and the NIHR
Treatment duration varies by indication and injury severity
Split products of GLP-1, GLP-1(737), GLP-1(937) and GLP-1(2837), as well as LacZ (control) carried in AVV vector system were injected into apoe / mice on high-fat diet